Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Cardiorenal outcomes"'
Autor:
Muhammad Usman Ali, G. B. John Mancini, Donna Fitzpatrick-Lewis, Kim A. Connelly, Eileen O’Meara, Shelley Zieroth, Diana Sherifali
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract Background The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) use. Since then, a
Externí odkaz:
https://doaj.org/article/d921599370584f67a43352d744ac5bd1
Autor:
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Abstract Background It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the cardiorenal risk in patients with type 2 diabetes (T2D). The purpose of this study is to provide an update of all large cardiovascular outc
Externí odkaz:
https://doaj.org/article/3c366d570ad24c4d8a1bcf39be258452
Autor:
Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito, Dario Giugliano
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-10 (2021)
Abstract Background Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the better glycemic contr
Externí odkaz:
https://doaj.org/article/9aedeaf813a14594b1a2323b1bd72ef0
Autor:
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini, Katherine Esposito
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Abstract Background A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM). Methods W
Externí odkaz:
https://doaj.org/article/350ec22390e74c53b7c53d0cd7a32144
Autor:
Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract Background Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of
Externí odkaz:
https://doaj.org/article/183d926e22824f2198fce8d59b95f101
Autor:
Wen Wei, Jin Liu, Shiqun Chen, Xinghao Xu, Dachuan Guo, Yibo He, Zhidong Huang, Bo Wang, Haozhang Huang, Qiang Li, Jiyan Chen, Hong Chen, Ning Tan, Yong Liu
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
ObjectiveSodium glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), heart failure (HF) or chronic kidney disease (CKD). However, whether or not the patients with
Externí odkaz:
https://doaj.org/article/bacfc02de69444f0bc4b140de8609c68
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lorenzo Scappaticcio, Katherine Esposito, Giuseppe Bellastella, Maria Ida Maiorino, Paolo Chiodini, Dario Giugliano, Miriam Longo
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-10 (2021)
Cardiovascular Diabetology
Cardiovascular Diabetology
Background Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the better glycemic control in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6733a7985674c04c67cf8dbfc527c69f
https://doaj.org/article/9aedeaf813a14594b1a2323b1bd72ef0
https://doaj.org/article/9aedeaf813a14594b1a2323b1bd72ef0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Antonio Ceriello, Miriam Longo, Katherine Esposito, Giuseppe Bellastella, Paola Caruso, Dario Giugliano, Lorenzo Scappaticcio, Maria Ida Maiorino, Paolo Chiodini
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Cardiovascular Diabetology
Cardiovascular Diabetology
Background A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM). Methods We did an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9e3d37fb03d26f466c29937ba81e9f
https://doi.org/10.1186/s12933-021-01366-8
https://doi.org/10.1186/s12933-021-01366-8